文献速递心力衰竭与心肌病肺血管病与心包/心肌炎

射血分数保留型心力衰竭中的右心室

Right ventricle in heart failure with preserved ejection fraction.
PubMed 文献 · Heart · 2020-09-07

本文综述射血分数保留型心力衰竭(HFpEF)中右心室功能障碍(RVD)的患病情况、病理生理机制、评估手段与治疗现状。RVD 在 HFpEF 患者中的发生率为 4%-50%,肺动脉高压与合并症常参与其发生;超声与心脏磁共振(CMR)是重要评估工具,现有靶向药物尚未显示改善 RVD。

要点

  • HFpEF 患者中 RVD 的发生率为 4%-50%,应重视右心评估。
  • 肺动脉高压及慢阻肺、肥胖、睡眠呼吸暂停、房颤等合并症可驱动 RVD。
  • 现有磷酸二酯酶抑制剂等靶向药物尚未显示改善 RVD,需探索新干预。

核心结论

  • 右心室功能障碍在 HFpEF 中并不少见,是理解该病与潜在治疗靶点的重要环节。

研究设计与样本

  • 综述性文章,围绕 HFpEF 中右心室的病理生理、评估方法与治疗进展进行论述。

主要发现

  • RVD 在 HFpEF 患者中的发生率为 4%-50%。
  • 肺动脉高压常参与 RVD 的病理生理过程。
  • 慢阻肺、肥胖、阻塞性睡眠呼吸暂停和心房颤动等合并症也可能驱动 HFpEF 中 RVD 的发生。
  • FDG PET 显像随 RVD 进展而 FDG 积聚增加,其应用价值与预后意义尚待进一步研究确认。

关键数值与推荐

  • 常用右心室功能测量指标包括面积变化分数、三尖瓣环收缩期位移和三尖瓣环收缩期速度。
  • 斑点追踪超声心动图与心脏磁共振(CMR)正受到关注,用于评估右心室结构、纤维形变与收缩功能。
  • 磷酸二酯酶抑制剂、鸟苷酸环化酶刺激剂、硝酸酯类和吸入无机亚硝酸盐等靶向药物治疗尚未显示改善 RVD。

临床怎么用

  • HFpEF 患者应评估右心室功能,可结合常规超声指标、斑点追踪与 CMR。
  • 管理上需关注肺动脉高压及慢阻肺、肥胖、睡眠呼吸暂停、房颤等合并症。
  • 现有靶向药物对 RVD 疗效未获证实,用药决策需个体化并关注新证据。

局限性

  • 本文为综述,未报告原始研究设计、样本量与效应值等具体数据。
  • FDG PET 在 RVD 中的应用价值与预后意义尚需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart failure. While previously neglected, the right ventricle (RV) has sparked interest in recent years as a means for better understanding this condition and as a potential therapeutic target.Right ventricular dysfunction (RVD) is present in 4%-50% of patients with HFpEF. The RV is intimately connected to the pulmonary circulation, and pulmonary hypertension is commonly implicated in the pathophysiology of RVD. The development of RVD in HFpEF may also be driven by comorbidities, such as chronic obstructive pulmonary disease, obesity, obstructive sleep apnoea and atrial fibrillation. The evaluation of RVD is particularly challenging due to anatomical and structural factors, as well as unique physiological characteristics of this chamber like load and interventricular dependency. Fractional area change, tricuspid annular plane systolic excursion and tricuspid annular systolic velocity are commonly used measurements of RV function. Speckle tracking echocardiography and cardiac magnetic resonance (CMR) are also gaining attention as important tools for the assessment of RV structure, fibre deformation and systolic performance. Further research is needed to confirm the utility and prognostic significance of RV [18F]fluorodeoxyglucose (FDG) positron emission tomography imaging as FDG accumulation is suggested to increase with progressive RVD. Targeted pharmacotherapy with phosphodiesterase inhibitors, guanylate-cyclase stimulators, nitrates and inhaled inorganic nitrites have yet to demonstrate improvement in RVD, compelling the need for evaluation and discovery of novel pharmacological interventions for this entity.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Berglund F, Piña P, Herrera CJ, et al. Right ventricle in heart failure with preserved ejection fraction. Heart. 2020. PMID: 32895314. doi:10.1136/heartjnl-2020-317342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。